Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
Proprietary R&D is led by a world-class team of medicinal chemists and industry veterans, ensuring innovative product development. A first-to-market product, unbuzzd addresses a fast-expanding consumer category, with 300% growth expected by 2030. Lucid-MS, a potential multi-billion-dollar asset, represents a significant breakthrough in the treatment of demyelinating diseases, supported by an expedited regulatory pathway. Strategic equity and royalty agreements with Celly Nutrition for consumer-focused alcohol misuse treatments provide an additional revenue stream. Quantum BioPharma is strategically positioned in two high-growth sectors: hangover remedies and MS therapeutics. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company committed to developing innovative…
